Skip to content

Study · Not a test of the peptide alone · 2006

2 results

Differential effects of insulin-like growth factors on scratch wound repair in respiratory epithelial cells.

Adams DH, McIntosh D, Wormald PJ, Cowin AJ

American journal of rhinology1 Nov 2006Cited by 4 (Europe PMC)

PMID17181112 (opens in a new tab)DOI10.2500/ajr.2006.20.2916 (opens in a new tab)PepBankPUB-17181112
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, IGF-1 LR3 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking IGF-1 LR3.

  1. 01LabNot a test of IGF-1 LR3 aloneIn vitro (cells)Efficacy outcome

    In human bronchial and tracheal epithelial cells, all analyzed growth factors, including the IGF-I analogue LongR3 IGF-I, significantly improved the rate of scratch closure.

    In plain wordsIn cells, every growth factor tested, including LongR3 IGF-I, sped up the closing of a scratch in lung airway cells.

    Peptide
    IGF-1 LR3
    Outcome
    IncreaseScratch closure rate in bronchial and tracheal epithelial cells
    Study

    humann: not reported in source

    Nasal, bronchial and tracheal epithelial cell lines, scratch assay
    Outcome group
    Wound healing · Respiratory

    Source sentences

    Summary
    All growth factors that were analyzed significantly improved the rate of scratch closure in bronchial and tracheal epithelial cells (p < or = 0.05).
    2 context sentences
    Summary · context
    Human epithelial cell lines from the nasal, bronchial, and tracheal regions were analyzed for their response to IGF-I and IGF-II, in a confluent monolayer scratch assay.
    Summary · context
    Consequently, the analogues LongR3 IGF-I, Des1-3 IGF-I and Arg3 IGF-I were investigated also because of their lower affinity for the IGFBPs, while still retaining unaffected affinity for the IGF-I receptor.

    In this study, IGF-1 LR3 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 LR3.

  2. 02LabNot a test of IGF-1 LR3 aloneIn vitro (cells)Efficacy outcome

    In human airway epithelial cells, the IGF-I analogues (LongR3, Des1-3 and Arg3 IGF-I) did not significantly improve scratch closure compared with IGF-I.

    In plain wordsIn cells, the IGF-I analogues, LongR3 IGF-I among them, did not close scratches better than IGF-I.

    Peptide
    IGF-1 LR3
    Outcome
    No significant changeScratch closure rate with IGF-I analogues versus IGF-I
    Study

    humann: not reported in source

    Nasal, bronchial and tracheal epithelial cell lines, scratch assay
    Comparator
    IGF-I
    Outcome group
    Wound healing · Respiratory

    Source sentences

    Summary
    The IGF-I analogues did not significantly improve scratch closure compared with IGF-I, despite the presence of IGFBP-3 in nasal, bronchial, and tracheal epithelial cells.
    2 context sentences
    Summary · context
    Human epithelial cell lines from the nasal, bronchial, and tracheal regions were analyzed for their response to IGF-I and IGF-II, in a confluent monolayer scratch assay.
    Summary · context
    Consequently, the analogues LongR3 IGF-I, Des1-3 IGF-I and Arg3 IGF-I were investigated also because of their lower affinity for the IGFBPs, while still retaining unaffected affinity for the IGF-I receptor.

    In this study, IGF-1 LR3 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 LR3.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.